Trial intelligence / Profile preview

EGFR-TKI versus EGFR-TKI + fulvestrant in advanced non-squamous NSCLC in women

2011-003571-11Phase 2Completed

Sponsor: IFCT
Start: Dec 2011
Modality: Small Molecules
Countries: 1

Overview

Phase 2, randomised trial of gefitinib, erlotinib and fulvestrant in non-small cell lung cancer (NSCLC) and Non-small cell lung cancer (NS-NSCLC) (2 arms), sponsored by IFCT. Primary endpoint: 3-month progression-free survival in EGFR wild-type patients. Started Dec 2011; status: completed.

Drugs

gefitiniberlotinibfulvestrant

Conditions

non-small cell lung cancer (NSCLC)Non-small cell lung cancer (NS-NSCLC)

Beyond the preview

Go deeper on 2011-003571-11.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2011-003571-11.